Impact of Hyperuricemia on Clinical Outcomes After Percutaneous Coronary Intervention for In-stent Restenosis

Overview

Journal BMC Cardiovasc Disord

Publisher Biomed Central

Specialty Cardiology & Vascular Diseases

Date 2018 Jun 13

PMID 29890945

Citations 3

Authors

Hyung Joon Joo

Han Saem Jeong

Hyungdon Kook

Seung Hun Lee

Jae Hyoung Park

Soon Jun Hong

Cheol Woong Yu

Do-Sum Lim

Affiliations

Soon will be listed here.

Abstract

Background: There have been limited data on the impact of hyperuricemia on long-term clinical outcomes after percutaneous coronary intervention (PCI) for in-stent restenosis (ISR).

Methods: From January 2009 to July 2015, 317 patients who underwent repeat PCI for ISR were divided into two groups: patients with normal serum uric acid (UA) levels (normal UA group) and patients with higher serum UA levels (higher UA group). The higher UA group included patients with serum UA levels > 6.8 mg/dL or patients who were taking anti-hyperuricemic medication.

Results: During a median follow-up period of 1088 days, the cumulative incidence rates of major adverse event (MAE), including a composite of all-cause death, non-fatal myocardial infarction, and any revascularization, were similar between the two groups (higher UA 36.4% vs. normal UA 29.9%, p = 0.389, log-rank p = 0.367). Follow-up angiographic data showed similar outcomes of late lumen loss (0.8 ± 0.9 mm vs. 0.8 ± 1.1 mm, p = 0.895) and binary restenosis rate (28.1% vs. 34.7%, p = 0.622). Multivariate Cox regression analysis indicated higher levels of low-density lipoprotein cholesterol (hazard ratio [HR] 1.011, 95% confidence interval [CI] 1.003-1.019, p = 0.006) and lower left ventricular ejection fraction (HR 0.972, 95% CI 0.948-0.996, p = 0.022), but not UA levels, to be the independent risk predictors of MAE.

Conclusion: Hyperuricemia is not associated with poor clinical outcomes after repeat PCI for ISR lesions.

Citing Articles

The Potential of Prognostic Biomarkers of Uric Acid Levels in Coronary Heart Disease Among Aged Population: A Scoping Systematic Review of the Latest Cohort Evidence.

Maulana S, Nuraeni A, Nugraha B J Multidiscip Healthc. 2022; 15:161-173.

PMID: 35115780 PMC: 8801359. DOI: 10.2147/JMDH.S340596.

Risk factors associated with intra-stent restenosis after percutaneous coronary intervention.

Alexandrescu D, Mitu O, Costache I, Macovei L, Mitu I, Alexandrescu A Exp Ther Med. 2021; 22(4):1141.

PMID: 34504587 PMC: 8394103. DOI: 10.3892/etm.2021.10575.

Pathophysiology of hyperuricemia and its clinical significance - a narrative review.

Skoczynska M, Chowaniec M, Szymczak A, Langner-Hetmanczuk A, Maciazek-Chyra B, Wiland P Reumatologia. 2020; 58(5):312-323.

PMID: 33227090 PMC: 7667948. DOI: 10.5114/reum.2020.100140.

References

Jing X, Wei X, Deng S, Du J, Liu Y, She Q . The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis. Clin Chim Acta. 2015; 446:248-52. DOI: 10.1016/j.cca.2015.04.038. View

Zhu W, Li J, Luo H, Wang G, Hua Q . Comparison of 2-year outcomes of repeated second-generation drug-eluting stent implantation for focal-type versus nonfocal-type in-stent restenosis. Coron Artery Dis. 2015; 26(7):587-91. DOI: 10.1097/MCA.0000000000000283. View

Jiang H, Liu W, Liu Y, Cao F . High levels of HB-EGF and interleukin-18 are associated with a high risk of in-stent restenosis. Anatol J Cardiol. 2015; 15(11):907-12. PMC: 5336941. DOI: 10.5152/akd.2015.5798. View

Zahn R, Hamm C, Schneider S, Richardt G, Kelm M, Levenson B . Coronary stenting with the sirolimus-eluting stent in clinical practice: final results from the prospective multicenter German Cypher Stent Registry. J Interv Cardiol. 2009; 23(1):18-25. DOI: 10.1111/j.1540-8183.2009.00513.x. View

Hsieh I, Chen C, Hsieh M, Yang C, Chen D, Chang S . Prognostic Impact of 9-Month High-Sensitivity C-Reactive Protein Levels on Long-Term Clinical Outcomes and In-Stent Restenosis in Patients at 9 Months after Drug-Eluting Stent Implantation. PLoS One. 2015; 10(9):e0138512. PMC: 4583430. DOI: 10.1371/journal.pone.0138512. View

Battelli M, Polito L, Bolognesi A . Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress. Atherosclerosis. 2014; 237(2):562-7. DOI: 10.1016/j.atherosclerosis.2014.10.006. View

Kuroda M, Otake H, Shinke T, Takaya T, Nakagawa M, Osue T . The impact of in-stent neoatherosclerosis on long-term clinical outcomes: an observational study from the Kobe University Hospital optical coherence tomography registry. EuroIntervention. 2015; 12(11):e1366-e1374. DOI: 10.4244/EIJY15M12_05. View

Jalal D, Chonchol M, Chen W, Targher G . Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2012; 61(1):134-46. PMC: 3525781. DOI: 10.1053/j.ajkd.2012.07.021. View

Kitahara H, Kobayashi Y, Takebayashi H, Nakamura Y, Kuroda N, Miyazaki A . Angiographic patterns of restenosis after sirolimus-eluting stent implantation. Circ J. 2009; 73(3):508-11. DOI: 10.1253/circj.cj-08-0720. View

10.

Lee S, Yoon C, Oh I, Suh J, Cho Y, Cho G . Angiographic patterns of restenosis with 2nd generation drug-eluting stent: comparative analysis from a 10-year single-center experience . Int Heart J. 2014; 56(1):6-12. DOI: 10.1536/ihj.14-072. View

11.

Yin Z, Fang Z, Yang M, Du X, Nie B, Gao K . Predictive value of serum uric acid levels on mortality in acute coronary syndrome patients with chronic kidney disease after drug-eluting stent implantation. Cardiology. 2013; 125(4):204-12. DOI: 10.1159/000350953. View

12.

Turak O, Canpolat U, Ozcan F, Mendi M, Oksuz F, Isleyen A . Usefulness of preprocedural serum uric acid level to predict restenosis of bare metal stents. Am J Cardiol. 2013; 113(2):197-202. DOI: 10.1016/j.amjcard.2013.09.004. View

13.

Liang S, Aiqun M, Jiwu L, Ping Z . TLR3 and TLR4 as potential clinical biomarkers for in-stent restenosis in drug-eluting stents patients. Immunol Res. 2015; 64(2):424-30. DOI: 10.1007/s12026-015-8685-6. View

14.

Dangas G, Claessen B, Caixeta A, Sanidas E, Mintz G, Mehran R . In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010; 56(23):1897-907. DOI: 10.1016/j.jacc.2010.07.028. View

15.

Almalla M, Pross V, Marx N, Hoffmann R . Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis. Coron Artery Dis. 2012; 23(7):492-6. DOI: 10.1097/MCA.0b013e328358a58f. View

16.

Zhao L, Zhu W, Zhang X, He D, Guo C . Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis. BMC Cardiovasc Disord. 2017; 17(1):16. PMC: 5217259. DOI: 10.1186/s12872-016-0445-6. View

17.

Becker M, Schumacher Jr H, Wortmann R, MacDonald P, Eustace D, Palo W . Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353(23):2450-61. DOI: 10.1056/NEJMoa050373. View

18.

Stone G, Moses J, Ellis S, Schofer J, Dawkins K, Morice M . Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007; 356(10):998-1008. DOI: 10.1056/NEJMoa067193. View

19.

Jinnouchi H, Kuramitsu S, Shinozaki T, Tomoi Y, Hiromasa T, Kobayashi Y . Difference of Tissue Characteristics Between Early and Late Restenosis After Second-Generation Drug-Eluting Stents Implantation　- An Optical Coherence Tomography Study. Circ J. 2017; 81(4):450-457. DOI: 10.1253/circj.CJ-16-1069. View

20.

Lee J, Rhee T, Hahn J, Hwang D, Park J, Park K . Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry. Int J Cardiol. 2017; 230:181-190. DOI: 10.1016/j.ijcard.2016.12.176. View